GWGeng Wang

Geng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Geng Wang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oxygen Vacancy‐Engineered CaCu 3 Ti 4 O 12 Nanocatalyst for Piezoelectrically Driven Cascade Apoptosis/Cuproptosis/Ferroptosis Therapy

    by Zekai Zhuang, Renlu Han, Yafei Hou, Qixiong Zhang, Jiancheng Yu, Na Li, Geng Wang, Jie Fu, Zhaozheng Deng, Hongwei Song, et al.

    Ultrasound (US) induced piezoelectric catalytic therapy is an emerging cancer treatment method. However, the development and optimization of piezoelectric catalyst remain the major challenge. Herein, we have converted the classical dielectric material CaCu 3 Ti 4 O 12 (CCTO) into an efficient piezoelectric material through oxygen vacancy (V O ) engineering, enabling piezoelectric catalytic‐driven cascade tumor therapy. The introduction of V O results in strong polarization and a robust piezoelectric coefficient. Density functional theory (DFT) calculations reveal that V O acts as an electron trap to suppress the recombination of electron and hole, enhancing the catalytic efficiency. The piezoelectric effect can “open” the cell membrane, facilitating the materials influx and triggering reactive oxygen species (ROS) storm. Meanwhile, the cavitation effect of US and tumor cell over‐expressed glutathione (GSH) accelerate Cu and Ca release, causing intracellular ions overload. ROS and Ca ions damage mitochondria to evoke apoptosis, which accordingly shuts down the Cu + outflow pathway and expedites cuproptosis. Moreover, ROS and GSH depletion triggers ferroptosis. This process establishes a positive feedback loop mechanism. Transcriptome sequencing confirms the activation of cell death‐related pathways. This study represents the first paradigm to create piezoelectricity through V O in CCTO for tumor therapy, advancing the applications of quadruple perovskites in tumor treatment.


  • Open Access

    The association of semaphorin 5A with lymph node metastasis and adverse prognosis in cervical cancer

    by Jian-Bing Xiao, Xin-Lei Li, Le Liu, Geng Wang, Song-Nan Hao, Hui-Juan Dong, Xue-Min Wang, Ya-Fang Zhang, Hui-Dong Liu

    Semaphorin 5A has been linked to tumor growth, invasion, and metastasis in pancreatic cancer. However, the role of semaphorin 5A in cervical cancer is not known. Our aim is to investigate the prognostic value of semaphorin 5A and its potential role in lymphangiogenesis and invasion in cervical cancer. In this study, pathological features and clinical data of 232 cervical cancer patients were retrospectively reviewed. Semaphorin 5A protein and mRNA expression was detected by immunohistochemistry and quantitative real-time reverse transcription-polymerase chain reaction, respectively. In vitro, we determined the role and mechanistic pathways of semaphorin 5A in tumor progression in cervical carcinoma cell lines. Semaphorin 5A expression was significantly higher in stage IIb tumors than in stage Ia, Ib, and IIa tumors. High semaphorin 5A expression was significantly associated with pelvic lymph node metastasis, lymphovascular permeation, and poor survival. Semaphorin 5A induced lymphangiogenesis through a plexin-B/Met/vascular endothelial growth factor-C pathway. Semaphorin 5A also increased cervical cancer cell invasion by stimulating the expression and activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 via PI3K/AKT and plexin-B3. Our findings indicate that semaphorin 5A may represent a poor prognostic biomarker and anti-metastasis therapeutic target in cervical cancer.


  • Open Access

    Oridonin inhibits aberrant AKT activation in breast cancer

    by Bowen Sun, Geng Wang, Huidong Liu, Pian Liu, Waleed O. Twal, Hiuwing Cheung, Steven L. Carroll, Stephen P. Ethier, Emily E. Mevers, Jon Clardy, et al.

    Oridonin inhibits aberrant AKT activation in breast cancer Oridonin inhibits aberrant AKT activation in breast cancer


  • Triptolide Suppresses Alkali Burn‐Induced Corneal Angiogenesis Along with a Downregulation of VEGFA and VEGFC Expression

    by Geng Wang, Na Li, Xiaohong Lv, Naila Ahmed, Xinlei Li, Huidong Liu, Jing Ma, Yafang Zhang

    Triptolide (TPL) is an active compound extracted from a Chinese herbal medicine tripterygium wilfordii Hook. f. (Celastraceae), which has been used as an anti‐inflammatory drug for years. It also inhibits the growth and proliferation of different types of cancer cells. The inhibitory effect of TPL on angiogenesis after chemical‐induced corneal inflammation was studied in vivo. The effects of TPL on the proliferation, apoptosis, migration, and tube formation of rat aortic endothelial cells (RAECs) were studied in vitro. Cell proliferation and apoptosis were measured by MTT assay and flow cytometry, respectively. Migration was analyzed using the scratch wound healing assay and transwell assay. Tube formation assay was used to examine angiogenesis. Real‐time PCR and Western blot were used to determine the expression of vascular endothelial growth factor A (VEGFA) and VEGFC. To study the in vivo effects of TPL, the mouse model of alkali burn‐induced corneal angiogenesis was used. The angiogenesis was analyzed by determining the density of the newly generated blood vessels in corneas. We found that TPL induced apoptosis and inhibited the proliferation of RAECs in a dose‐dependent manner. TPL inhibited migration and tube formation of RAECs and decreased the expression of VEGFA and VEGFC in vitro. Furthermore, TPL suppressed alkali burn‐induced corneal angiogenesis and inhibited the expression of VEGFA and VEGFC in corneas in vivo. In conclusion, topical TPL as a pharmacological agent has the ability to reduce angiogenesis in cornea and may have clinical indications for the treatment of corneal angiogenesis diseases which have to be further explored. Anat Rec, 300:1348–1355, 2017.


    • 25 January 2017
      • Vol. 20  (1) , 62-66

    [Association of peripheral nerve invasion with clinicopathological factors and prognosis of colorectal cancer].

    by Dong Han, Ying Wei, Xidi Wang, Geng Wang, Yinggang Chen

    To investigate the association of peripheral nerve invasion (PNI) with clinicopathological factors and prognosis of colorectal cancer. Clinicopathological data and Surgical specimens of 372 colorectal cancer patients who underwent radical resection from January 2011 to June 2012 in The Second Affiliated Hospital of Harbin Medical University were collected. Histopathological evaluation of tissue samples was conducted with hematoxylin and eosin-stained sections. PNI was considered positive when cancer cells were observed inside the nerve sheath, or when at least 33% of the nerve periphery was surrounded by cancer cells. The relationship between PNI and clinicopathological factors of colorectal cancer was analyzed by χ2 test or Fisher's exact test. Three-year overall survivals of PNI positive and negative patients were determined using the Kaplan-Meier method. Detection results were compared using log-rank test. Of 372 colorectal cancer patients, 133 (35.8%) were PNI positive. Among the PNI positive patients, 63 cases were male and 70 cases female; 76 cases were more than 60 years old and 57 cases less than 60 years old; tumors of 6 cases located in the ileocecal colon, of 33 cases in the ascending colon, of 7 cases in the transverse colon, of 8 cases in the descending colon, of 22 cases in the sigmoid colon, and of 57 cases in the rectum; tumor diameter was greater than 4 cm in 83 cases, and less than 4 cm in 50 cases; tumors of 48 cases were moderately or highly differentiated, and of 85 cases poorly-differentiation; tumor invasion depth in 2 cases, T2 in 7 cases, T3 in 93 cases, T4 in 31 cases; lymphatic metastasis was N0 phase in 56 cases, N1 in 41 cases, and N2 in 36 cases; tumors were stage I( in 2 cases, stage II( in 40 cases, of stage III( in 75 cases and stage IIII( in 16 cases. The positive rate of PNI was significantly associated with tumor location (χ2=11.20, P=0.048), tumor size (χ2=21.80, P=0.000), differentiation (χ2=60.90, P=0.000), depth of invasion (χ2=19.00, P=0.000), lymph node metastasis (χ2=19.70, P=0.000) and TNM staging (χ2=70.80, P=0.000), but not with sex, age or vascular invasion(P>0.05). The median follow-up time was 48 (8 to 62) months. Kaplan-Meier survival curve showed that the 3-year survival rate of PNI positive patients was 52.6%, significantly lower than that of PNI negative patients(78.3%, P=0.000). Further analysis of patients with stage II( and III( colorectal cancer showed that the 3-year survival rates of PNI positive patients were 62.3% and 43.5%, respectively, which were significantly lower than those of PNI negative patients with stage II( and III((91.7% and 79.4%), and the differences were statistically significant(P=0.000). PNI is a poor prognostic factor of colorectal cancer. It may be a complement of the classic TNM staging classification in stratifying colorectal cancer patients, especially in stages II( and III(.


    • 1 December 2015
      • Vol. 36  (7) , 689-94

    Cerebrospinal fluid oxytocin correlated with peripheral ALT and AST in Chinese female subjects.

    by Yang Yu, Yimin Kang, Guoshi Qiu, Hong Lin, Jinzhong Xu, Xiaofang Wang, Longteng Xie, Yongsheng Jiang, Baofu Jia, Pengxiang Wang, et al.

    Oxytocin (OT) is primarily synthesized in the paraventricular nucleus of the hypothalamus and supraoptic nucleus of the hypothalamus in the central nervous system and exhibits a wide spectrum of central and peripheral activities. OT is involved in lipid metabolism and glucose homeostasis and plays a protective role against liver damage. In this study, we investigated whether CSF OT levels correlates with peripheral glucose, lipid profiles, and/or liver enzymes in Chinese subjects. Sixty-nine subjects (n=36 males; n=33 females) who were recruited from Beijing Jishuitan Hospital participated in the study. Their levels of CSF OT and peripheral parameters were assayed by radioimmunoassay and continuous monitoring assay, respectively. There was no significant difference in CSF OT levels between males (53.09±6.88 nmol/mL) and females (52.34±6.87 nmol/mL), and no correlation found between CSF OT levels and peripheral glucose and lipid profiles. Significant negative correlation was observed between CSF OT levels and peripheral ALT and AST concentration in females but not in males. Our results support the physiological role of neuropeptides acting on brain sites to regulate liver enzymes, and shed new light on the brain-liver interaction.

  • Predicting Chemosensitivity to Gemcitabine and Cisplatin Based on Gene Polymorphisms and mRNA Expression in Non-Small-Cell Lung Cancer Cells

    by Xiangning Meng, Geng Wang, Rongwei Guan, Xueyuan Jia, Wei Gao, Jie Wu, Jingcui Yu, Peng Liu, Yang Yu, Wenjing Sun, et al.

    Aim: We used a panel of 17 non-small-cell lung cancer cell lines to investigate whether the presence of polymorphisms in the RRM1, ERCC1, ABCB1 and MTHFR genes and alterations in their mRNA expression can affect the in vitro chemosensitivity to cisplatin and gemcitabine. Materials & methods: Polymorphisms in these genes were evaluated by direct sequencing. mRNA expression levels were assessed by realtime PCR. In vitro chemosensitivity to cisplatin and gemcitabine was expressed as IC50 values, using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Results: There was a significant, positive correlation between RRM1 mRNA expression and IC50 values for gemcitabine (r = 0.6533, p = 0.0045), and there was a significant, negative correlation between ABCB1 mRNA expression and IC50 values for cisplatin (r = -0.5459, p = 0.0287). When examining the association between the polymorphisms and IC50, we found that only the MTHFR 1298A>C polymorphism showed a tendency to be more chemosensitiv...


  • Adenosine receptor expression in a rat model of experimental autoimmune myasthenia gravis

    by Na Li, Geng Wang, Xiuhua Yao, Qingfei Kong, Xiaoyu Shang, Xiaoli Xie, Jinghua Wang, Xiaoying Kang, Lianhong Jin, Guangyou Wang, et al.


  • JAM-C promotes lymphangiogenesis and nodal metastasis in non-small cell lung cancer

    by SongNan Hao, YanMei Yang, Yan Liu, ShuCai Yang, Geng Wang, JianBing Xiao, HuiDong Liu

    This study aims to investigate lymphatic metastasis-related genes in non-small cell lung carcinomas (NSCLC). NSCLC tissue was analyzed for expression of junctional adhesion molecule-C (JAM-C) protein. Our data revealed novel associations between JAM-C overexpression in primary tumors and lymphatic microvessel density (LMVD), lymph node metastasis, and poorer overall survival and recurrence-free survival. We used the highly metastatic human lung adenocarcinoma cell line Anip973 and its parental line AGZY83-a, which has a low metastatic capacity, in vivo and vitro. We found that JAM-C played an important role in different metastasis capacity of lymph node. JAM-C affected tumor growth, LNM, JAM-C, VEGF-C, vasculature, and ERK1/2 phosphorylation (p-ERK1/2). β1 integrin was involved in lymph node metastasis. Moreover, JAM-C knockdown in highly metastatic Anip973 decreased cell migration in scratch-wound assays. The JAM-C knockdown in Anip973 cells and JAM-C cDNA in AGZY83-a cells regulated the vascular endothelial growth factor C (VEGF-C) expression. Immunofluorescence showed that blocked VEGF-C expression in JAM-C shRNA Anip973 cells were restored after JAM-C treatment. JAM-C-induced VEGF-C in JAM-C cDNA AGZY83-a cells was also effectively inhibited by treatment with an antibody specifically against JAM-C. Use of media from Anip973 cells, AGZY83-a, and A549cells lung cancer cells that overexpressed or downregulated JAM-C was demonstrated to affect activity of VEGF-C-induced β1 integrin subunit or ERK activity in human dermal lymphatic endothelial cells (HDLEC) treated with VEGF-C or inhibitory antibody to JAM-C. Overall, these results indicate that JAM-C could mediate metastasis as it contributes to VEGF-C expression in cancer cells. JAM-C affects β1and ERK activation in HDLEC, thus promoting lymphangiogenesis and nodal metastasis. Our findings indicate that JAM-C may be a therapeutic target for preventing and treating lymphatic metastases.


  • ATP‐binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non‐small cell lung cancer cells

    by Xiangning Meng, Geng Wang, Peng Liu, Jingmei Hou, Yan Jin, Yang Yu, Jing Bai, Feng Chen, Wenjing Sun, Songbin Fu

    Background and objective: The adenosine triphosphate (ATP)‐binding cassette, sub‐family B, member 1 (ABCB1) gene encodes P‐glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel.ABCB1gene polymorphisms may alter the expression and function of Pgp, thereby influencing the response to chemotherapy. A panel of 17 non‐small cell lung cancer (NSCLC) cell lines was used to investigate whether alterations in theABCB1gene or its mRNA expression correlated within vitrochemosensitivity to paclitaxel.Methods: Polymorphisms in theABCB1gene were evaluated by direct sequencing. mRNA expression levels were assessed by quantitative real‐time reverse transcription PCR.In vitrochemosensitivity to paclitaxel was expressed as half‐maximal inhibitory concentration values, using a tetrazolium (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide)‐based colorimetric assay.Results: The variant allele frequencies for fourABCB1gene polymorphisms were 14.71% for 2677G>T/A, 32.35% for 2734T>C, 23.53% for 3396C>T and 76.47% for 3435C>T. There was a significant positive correlation betweenABCB1mRNA expression and half‐maximal inhibitory concentration values for paclitaxel (r = 0.5322,P = 0.0279). None of the fourABCB1gene polymorphisms were associated with paclitaxel chemosensitivity orABCB1mRNA expression in the 17 cell lines.Conclusions: Thesein vitroresults suggest that highABCB1mRNA expression may be a predictive biomarker for poor chemosensitivity to paclitaxel. The panel of NSCLC cell lines may provide clues and indications for establishing clinically useful relationships between a given polymorphism or level of gene expression and chemosensitivity to an anti‐cancer agent.